Olanzapine Glenmark

The European Commission granted a marketing authorisation valid throughout the EU for Olanzapine Glenmark on 3 December 2009.

For more information about treatment with Olanzapine Glenmark, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

The recommended starting dose of Olanzapine Glenmark depends on the disease being treated: 10 mg per day is used in schizophrenia and in the prevention of manic episodes, and 15 mg per day in the treatment of manic episodes, unless it is used with other medicines, in which case the starting dose can be 10 mg per day. The dose is adjusted according to how well the patient responds to and tolerates the treatment. The usual dose range is between 5 and 20 mg per day. Patients over 65 years of age and patients who have reduced liver or kidney function may need a lower starting dose of 5 mg per day.

The active substance in Olanzapine Glenmark, olanzapine, is an antipsychotic medicine. It is known as an ‘atypical’ antipsychotic because it is different from the older antipsychotic medicines that have been available since the 1950s. Its exact mechanism of action is unknown, but it attaches to several different receptors on the surface of nerve cells in the brain. This disrupts signals transmitted between brain cells by ‘neurotransmitters’, chemicals that allow nerve cells to communicate with each other. It is thought that olanzapine’s beneficial effect is due to it blocking receptors for the neurotransmitters 5-hydroxytrypamine (also called serotonin) and dopamine. Since these neurotransmitters are involved in schizophrenia and in bipolar disorder, olanzapine helps to normalise the activity of the brain, reducing the symptoms of these diseases.

The CHMP concluded that, in accordance with EU requirements, Olanzapine Glenmark has been shown to have comparable quality and to be bioequivalent to Zyprexa. Therefore, the CHMP’s view was that, as for Zyprexa, the benefit outweighs the identified risk. The Committee recommended that Olanzapine Glenmark be given marketing authorisation.

Olanzapine Glenmark is a medicine containing the active substance olanzapine. It is available as tablets (2.5, 5, 7.5, 10, 15 and 20 mg).

Olanzapine Glenmark is a ‘generic medicine’. This means that Olanzapine Glenmark is similar to a ‘reference medicine’ already authorised in the European Union (EU) called Zyprexa.

Olanzapine Glenmark is used to treat adults with schizophrenia. Schizophrenia is a mental illness that has a number of symptoms, including disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (mistaken beliefs). Olanzapine Glenmark is also effective in maintaining improvement in patients who have responded to an initial course of treatment.

Olanzapine Glenmark is also used to treat moderate to severe manic episodes (extremely high mood) in adults. It can also be used to prevent the recurrence of these episodes (when symptoms come back) in adults with bipolar disorder (a mental illness with alternating periods of high mood and depression) who have responded to an initial course of treatment.

The medicine can only be obtained with a prescription.

Because Olanzapine Glenmark is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine Zyprexa. Medicines are bioequivalent when they produce the same levels of the active substance in the body.

Because Olanzapine Glenmark is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine's.